Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 27.00
Ask: 28.00
Change: -0.50 (-1.79%)
Spread: 1.00 (3.704%)
Open: 28.00
High: 29.00
Low: 27.50
Prev. Close: 28.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 07:00

RNS Number : 1837S
Renalytix AI PLC
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Renalytix AI Plc

213800NTOH3FK3WER551

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

 

02nd July 2020

 

6. Date on which issuer notified (DD/MM/YYYY):

 

06th July 2020

 

 

7. Total positions of person(s) subject to the notification obligation

 

 

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

59,416,134

Position of previous notification (if

applicable)

3.11%

-

3.11%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWL4Y04 (L&G)

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Group (Direct)

Below 3%

Below 3%

 

Legal & General Assurance Society (Direct)

 

Below 3%

 

Below 3%

 

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Group (Direct)

Below 3%

Below 3%

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Go ETF Solutions

Below 5%

Below 5%

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

 

 

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 59,416,134

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

06/07/2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFZGGNRVNGGZM
Date   Source Headline
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.
7th Dec 20203:45 pmRNSResult of AGM
2nd Dec 20201:08 pmRNSPartnership with National Kidney Foundation
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:35 pmRNSPrice Monitoring Extension
25th Nov 20207:00 amRNSFinancial Results for First Quarter of FY 2021
13th Nov 20207:00 amRNSStifel 2020 Healthcare Conference
6th Nov 20207:00 amRNSChange of Adviser
2nd Nov 20203:30 pmRNSPosting of Annual Report & Accounts &Notice of AGM
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering
13th Jul 202012:01 pmRNSLaunch of Global Offering and application to list
13th Jul 202011:45 amRNSResult of General Meeting
8th Jul 20207:01 amRNSApproval of distribution of shares in Verici Dx
8th Jul 20207:00 amRNSPartnership with America’s Choice Provider Network
7th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSKidneyIntelX study accepted for publication
30th Jun 20207:00 amRNSUniversity of Michigan Partnership & Data Sharing
25th Jun 20207:01 amRNSProposed Board changes; Circular & Notice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.